

MAGNESIUM

PRESENTATION: Ampoules containing magnesium sulphate 50% equivalent to 2mmol/ml: 10ml ampoules.

INDICATION: Correction of hypomagnesaemia. Normal range: 0.7 – 1.0 mmol/l.
Treatment of hypomagnesaemia associated with arrhythmias.
Severe bronchospasm.

DOSE AND ADMINISTRATION: **ICU STANDARD INTRAVENOUS INFUSION**

For treatment of hypomagnesaemia:

Peripheral administration:

20mmol in 250ml glucose 5% over 4 hours.

Central administration:

20mmol in 100ml glucose 5% over 4 hours.

For treatment of severe acute asthma:

8mmol (2g) in 50mls glucose 5% over 20 minutes, peripherally or centrally.

For treatment of serious arrhythmias:

8mmol (2g) in 50mls glucose 5% over 20 minutes, peripherally or centrally. Dose may be repeated once if necessary.

STABILITY: Physically and chemically stable for 24 hours at room temperature.

ADDITIONAL NOTES: Also stable in sodium chloride 0.9%.

References

1. Norohna J et al. Magnesium in critical illness: metabolism, assessment and treatment. Intensive Care Medicine 2002;28:667-79.
2. Magnesium sulphate 50% Injection. Summary of Product Characteristics. Martindale Pharma. Last updated 25/09/20. <https://www.medicines.org.uk/emc/product/3539/smpc> .Accessed 21/10/20.
3. Magnesium sulphate. Version 10. The UK Injectable Medicines Guide. Accessed 21/10/20.
4. BNF App, Version 3.0.1. Updated 02/09/20.
5. NHS Lothian University Hospitals Division-Adult Medical Emergencies Handbook. 2009/2011.

Title: Magnesium	
ID: TOPG140612v1	Lead Author: Claire Hannah
Category: 1	Document Version; 4
Status Draft/Final: Final	Review Date: October 2022
Authoriser; Lothian Critical Care Directorate Editorial Board.	Date Authorisation: October 2020
Date added to intranet: November 2020	
Key Words;	
Comments;	

**Critical Care Guidelines
OR CRITICAL CARE USE ONLY**